|
|
|
|
| Join us on August 25th to learn how to optimize Parkinson's disease clinical trials. Experts from Dr. Vince Clinical Research and the Davis Phinney Foundation will discuss trial design, endpoint selection, patient-centered research, and operational challenges for symptomatic and disease-modifying therapies. Attendees will gain practical strategies, real-world case studies, and insights to support successful CNS drug development from early-phase studies through NDA submission. |
|
|
|
| Digital Twins Enhance Disease Progression Measurements In FSHD | Guest Column | A conversation between Amber Salzman, Ph.D., and Clinical Leader executive editor Abby Proch | Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy. |
|
|
| Rapid Expansion Of Peptide And Nanobody Drug Conjugates | White Paper | Citeline | Peptide and nanobody drug conjugates are gaining momentum, with 106 active programs identified globally. Learn about the fast-evolving space for targeted drug delivery and competitive opportunities. |
|
|
|
| Rescuing A Global Full-Service Phase III Trial | Case Study | Worldwide Clinical Trials Oncology | This case underscores the expertise employed in a comprehensive strategy and set of services that were used to salvage a Phase III clinical trial for ovarian cancer and ensure its timely completion. |
|
|
|
|
|
| Reviewing Protocols Across Therapeutic Areas | Product | BRANY | A successful clinical trial starts with an efficient protocol review. Explore how to get your clinical trial to the start line while ensuring participant health and safety. |
|
|
|
| Forget More Clinical Tech, We Need More Adoption | From The Editor | By Dan Schell, Chief Editor, Clinical Leader | At SCOPE Summit, Craig Lipset shared a blunt assessment of clinical trial innovation: the tools exist, regulators are engaged, and digital approaches offer clear quality advantages — yet adoption remains the industry’s biggest hurdle. From evolving FDA inspection expectations to the normalization (and lingering misconceptions) of decentralized trials, Lipset argues progress will depend less on new technology and more on scaling what already works. |
|
|
|
|
|
CHOOSE YOUR OWN ADVENTURE |
|
|
|
| You're receiving the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. To make changes to your newsletter selections, update your topic preferences. - Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
- Clinical Trial Technology (Tuesday)
- Decentralized Trials | Trial Management (Wednesday)
- Outsourcing Models | Regulatory & Compliance (Thursday)
- Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here. |
|
|
| Connect With Clinical Leader: |
|
|
|
